Evidence map›Paper›PMID 39644100›Full record

ArticleInternational journal of immunopathology and pharmacology

Prognostic impact of matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) in Egyptian breast cancer patients.

Fayrouz A Fouad, Mohamed A Khali, Inas Moaz, Hossam Elmasry, Nada Gheta, Asala Abdeen, Mariam Tantawi, Ganna Elkholy, Shaimaa Rihan, Mahmoud M Kamel and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fayrouz A FouadBaheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt.ORCID 0000-0001-6464-8701
Mohamed A KhaliClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0001-8310-3563
Inas MoazNational Liver Institute, Menoufia University, Menoufia, El-Kom, Egypt.
Hossam ElmasryBaheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt.ORCID 0000-0001-8273-6246
Nada GhetaFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt.
Asala AbdeenFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt.
Mariam TantawiFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt.
Ganna ElkholyFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt.
Shaimaa RihanBiochemistry Department, Faculty of Science Ain Shams University, Cairo, Egypt.
Mahmoud M KamelClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0003-0264-3096
Ayman El-Meghawry El-KenawyDepartment of pathology, College of Medicine, Taif University, Taif, Saudi Arabia.
Youssef As Abdel-MoneimFaculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.ORCID 0000-0002-3320-403X
Abdallah M GameelClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to investigate the diagnostic and prognostic relevance of MMP-2 and MMP-9 as biomarkers for breast cancer, as well as their association with clinicopathological factors. Breast cancer is a leading contributor to cancer-related deaths among women worldwide. The discovery of biomarkers is crucial for early diagnosis, outcome prediction, and effective treatment. Matrix metalloproteinases (MMPs) play a significant role in various physiological and pathological activities, including development, tissue repair, inflammation, cancer spread, and metastasis. While the prognostic significance of MMP-2 and MMP-9 levels in breast cancer has been studied, the findings remain inconclusive. Participants were divided into three groups, with each group consisting of 62 individuals: Group I comprised healthy controls, Group II consisted of newly diagnosed breast cancer patients (stage I-III), and Group III included patients with metastatic breast cancer. Levels of MMP-2 and MMP-9 were evaluated in these groups using the ELISA method. An evident increase in MMP-2 and MMP-9 levels was noted when comparing the control group with both the breast cancer and metastatic groups. Furthermore, a notable correlation was identified between serum MMP-9 levels and the pathological diagnosis of breast cancer (

Indexed as

Biomarkers, TumorBreast NeoplasmsMatrix Metalloproteinase 2Matrix Metalloproteinase 9AdultAgedCase-Control StudiesEgyptFemaleHumansMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanMMP9 protein, humanbiomarkerbreast cancerEgyptianMMP-2 and MMP-9

Identifiers

PMID39644100
PMCPMC11624540

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.